AMMF’s Hybrid 2025 European Cholangiocarcinoma Conference
Cholangiocarcinoma: A fairer deal, faster
Rethinking Liver Cancer
AMMF was delighted to welcome Dr Heinz-Josef Klümpen and Ms Rachel Guest, two internationally renowned specialists at the forefront of the CCA world, to co-chair AMMF’s conference 2025.
Under the theme, ‘Cholangiocarcinoma: A fairer deal, faster – Rethinking Liver Cancer’ the co-chairs brought together an international faculty of some 40 speakers, who explored the challenges faced and advances made in the understanding of CCA, together with the importance of accelerating the progress we are now seeing.
To view the 3-day programme, click here.
All 2025 sessions are available to watch again
The AMMF 2025 European Cholangiocarcinoma Conference is over but all the presentations from each of the three days, 07, 08 and 09 May 2025, are available to watch again:
- For registered delegates: The virtual conference platform remains live for those registered delegates by using their original login details. Access in this way will remain available until early in 2026.
- For those who didn’t register for the conference: All the individual presentations have been uploaded to AMMF’s website and are available to view by clicking here.
We very much hope that you will re-visit the event and join any sessions that you might have missed or would like to see again.
Please note: To abide by ABPI regulations, some parts of the conference programme and meeting platform are intended for Healthcare Professionals only.
Poster Presentations 2025
All the posters shown in the Poster Hall at AMMF’s Hybrid European Cholangiocarcinoma Conference 2025, can be seen by clicking here.
Please note: The Poster area is intended for HCPs only.
AMMF’s 2025 Conference in images
To see a selection of images capturing an event full of inspiration, information, networking and new collaborations, click here.
BASL Endorsed
AMMF’s 2025 Cholangiocarcinoma Conference is a
BASL* endorsed event.
*British Association for the Study of the Liver
CPD Accredited
AMMF’s Conference 2025 is a CPD accredited event.
Attendance is worth 19.5 hours CPD.
AMMF HPB Nurse Study Day – 07 May 2025
Running alongside the patient and carer sessions on Day One of AMMF’s 2025 annual conference, we hosted a study day with our Clinical Nurse Specialist (CNS) Advisory Board and extended international network of hepatobiliary (HPB) nurses. This study day was for registered nurses only, and was not available to a virtual audience.
The event provided a valuable opportunity to harness the collective expertise and first-hand experiences of the participating nurses.
To view the programme, click here.
RCN Accredited until 16 February 2026. Accreditation applies only to the educational content and not to any product, RCN cannot confirm competence of any practitioner. Attendance is worth 3.5 hours CPD
Hepatoma Research – Official Journal of AMMF’s European CCA Conference 2025
Hepatoma Research is an international peer-reviewed, gold open access, online academic journal founded by OAE Publishing Inc in April 2015 (oaepublish.com)
The journal is indexed in ESCI, Scopus and CAS, 2023 CiteScore: 3.2, first 2023 IF: 1.7 (Q3).
The journal aims to provide the best academic exchange platform in the field of liver cancer, including its occurrence, development, diagnosis, and treatment. The coverage also extends to other basic and clinical studies related to surgery, internal medicine, cell biology, pathology, pathophysiology, immunology, genetics, pharmacology, etc. https://www.oaepublish.com/hr
AMMF Conference Sponsors 2025
AstraZeneca is honoured to be a platinum sponsor of AMMF’s 2025 Conference for the third consecutive year. AMMF’s dedication to advancing research and improving outcomes for those with cholangiocarcinoma deeply resonates with our Cancer: Project Zero ambition to one day eliminate cancer as a cause of death. Project Zero is a non-promotional campaign funded, initiated and developed by AstraZeneca UK.
We are committed to addressing the disparities in cholangiocarcinoma, where many are diagnosed late, and approximately half (50.5%) receive no treatment. Supporting earlier diagnosis, treatments, and improved care pathways is essential for delivering fair and faster care.
By driving research and scientific advancement, AstraZeneca is committed to transforming care and outcomes for cholangiocarcinoma patients, ultimately moving us closer to a future where cancer is no longer a cause of death.
Anna Arent, Head of Oncology, AstraZeneca UK
References: 1. Jose S, Zalin-Miller A, Knott C, Paley L, et al., World J Gastrointest Oncol. 2023 Dec 15;15(12):2077-2092.
Veeva ID: Z4-73442
Date of preparation: April 2025
To read “Advancing Towards Zero: AstraZeneca’s Commitment to Transforming Cancer Outcomes”, click here
Jazz Pharmaceuticals: to see the article by Tomas Skacel, MD, PhD, Vice President, Medical Affairs for the Europe and International Region, click here.
Servier: to see the article from Servier re their commitment to health and innovation, click here.
All AMMF’s sponsors have supported AMMF’s 2025 Conference through a financial contribution only. They have not been involved in the content nor in any other aspect of the conference.
